MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-12-2026
Plus Therapeutics Cash Conversion Cycle 2011-2026 | PSTV
Annual Cash Conversion Cycle Plus Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | -336 M | - | 729 | 537 | 363 | 418 | 547 | 419 | 247 | 393 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 729 | -336 M | -37.3 M |
Quarterly Cash Conversion Cycle Plus Therapeutics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 87.4 | - | 18.9 | 32.1 | 26 | 18.9 | 28.3 | 13.7 | 107 | 77.3 | 155 | 101 | 78.5 | 61.7 | 125 | 59.5 | 116 | 45.9 | 219 | 121 | 239 | 140 | 234 | 269 | 265 | 90.3 | 273 | 184 | 191 | 99.3 | 96.6 | 85.5 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 273 | 13.7 | 118 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
3.11 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MannKind Corporation
MNKD
|
349 | $ 3.56 | 24.48 % | $ 1.09 B |  USA |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Bio-Techne Corporation
TECH
|
197 | $ 47.41 | -16.36 % | $ 7.47 B | USA |
 |
United Therapeutics Corporation
UTHR
|
192 | $ 596.76 | 4.29 % | $ 26.4 B | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
INmune Bio
INMB
|
19.9 K | $ 1.52 | -1.3 % | $ 37.6 M | USA |
 |
Exelixis
EXEL
|
-8.32 | $ 48.7 | 9.64 % | $ 13.2 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
257 | $ 21.48 | -3.89 % | $ 3.56 B | USA |
 |
Fortress Biotech
FBIO
|
-74.9 | - | - | $ 71.1 M | USA |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.15 | 1.19 % | $ 655 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
158 | $ 24.17 | 3.2 % | $ 3.08 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 55.08 | 5.15 % | $ 4.95 B |  Schweiz |
 |
Autolus Therapeutics plc
AUTL
|
119 | $ 1.7 | 3.66 % | $ 452 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Завод ДИОД
DIOD
|
-32.7 | - | - | - | Russia |